Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q1 FY14 Earnings Presentation
14 slides from Ajanta Pharma's earnings presentation, Jul 29, 2013
Slide 1: Investor Update – Q1 FY14
Investor Update – Q1 FY14 July 29, 2013 1
Slide 2: Highlights Q1 FY14 (Stand Alone)
Highlights Q1 FY14 (Stand Alone) Q1 FY14 Q1 FY13 ` Crs Revenue 219 174 26% EBITDA 51 37 38% PBT 48 23 106% PAT 33 20 66% July 29, 2013 V04 2
Slide 3: Revenue Break-up
Revenue Break-up Other Other Income, 3% Income, 0% Exports, Domestic, 53% 48% Domestic, Q1 FY14 Q1 FY13 43% Exports, 50% Other Income, 1% Other Op. Other Op. Income, 1% Income, 2% Domestic, 34% FY13 Exports, 64% Other Op. Income, 1% July 29, 2013 V04 3
Slide 4: Cost Break-up
Cost Break-up PAT, 15% Material Cost, 34% Other cost, PAT, 11% 25% Material Cost, 37% Other cost, 28% Q1 FY2013-14 Q1 FY2012-13 Tax, 7% Int, 0% Staff Cost, Dep., 4% 15% Tax, 2% Staff Cost, Int, 3%Dep., 4% 15% July 29, 2013 V04 4
Slide 5: India Business - Rankings
India Business - Rankings Revenue `96crs Growth 14% 9 new products launched for the quarter Healthy Numbers Segment Growth Rank (Q1 FY 14 MAT) (IMS MAT Jun’13) Ophthalmology 20% 5 Dermatology 33% 15 Cardiology 36% 27 Ajanta Pharma 29% 45 July 29, 2013 V04 5
Slide 6: India Business – Segments
India Business – Segments Others 7% Ophthal Others 7% Ophthal Inst. 26% 21% 23% Inst. 17% Domestic Domestic Break-up Break-up Q1 FY’13 Q1 FY’14 Cardio Derma Cardio Derma 25% 28% 20% 26% July 29, 2013 V04 6
Slide 7: Emerging Markets – Regional Contribution
Emerging Markets – Regional Contribution Latam 3% Latam 2% Q1 FY14 Q1 FY13 Africa 54% Africa Asia 43% Asia 41% 57% July 29, 2013 V04 7
Slide 8: Regulated Markets – ANDA Status
Regulated Markets – ANDA Status Total ANDAs filed – 15 (1 in Q1 FY14) Under Approval - 13 Approved – 2, Launched - 1 Balance Approvals expected in FY13/FY14 New team joining US Targeted filing every year – 5 to 6 July 29, 2013 V04 8
Slide 9: Consistent track record of growth
Consistent track record of growth 23% 53% CAGR Consolidated Revenue & PAT CAGR Revenu (` Crs.) PAT e 1000 120 930 112 100 800 677 80 600 77 499 60 409 400 349 309 51 40 230 238 199 34 200 145 25 20 10 22 2 15 12 0 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Total Income Profit After Tax July
Slide 10: Profit & shareholder returns
Profit & shareholder returns 112 EBITDA 230 (` Crs.) PAT (` Crs.) 77 138 51 99 80 34 68 25 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 Dividend 17 (` Crs.) EPS 48 (`) 10 33 7 22 5 15 3 11 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 1 July 29, 2013 V04 0
Slide 11: Key financial indicators
Key financial indicators ` FY09 FY10 FY11 FY12 FY13 Q1 FY14 (Q1 FY13) EPS 11 14 21 33 48 14 (8) Cash EPS 17 23 32 46 62 18 (12) EBITDA per share 29 34 42 62 98 22 (16) EBITDA margin 19% 19% 20% 22% 24% 23% (21%) PAT margin 7% 8% 10% 11% 12% 15% (11%) 1 July 29, 2013 V04 1
Slide 12: Project Progress
Project Progress • Dahej work in full swing • 50% civil work completed • Approvals under process for Savli • To commence work post monsoon 1 July 29, 2013 V04 2
Slide 13: Going Forward
Going Forward Growth Momentum continues India business growing above industry average Expected to continue the trend in coming quarters Emerging market business shows improved growth Depreciating rupee giving positive impact US market entry on schedule 1 July 29, 2013 V04 3
Slide 14: Thank You
Thank You SAFE HARBOUR STATEMENT This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also d